Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Farnesoid X receptor mediates macrophage-intrinsic responses to suppress colitis-induced colon cancer progression
Xingchen Dong, Ming Qi, Chunmiao Cai, Yu Zhu, Yuwenbin Li, Sally Coulter, Fei Sun, Christopher Liddle, Nataliya V. Uboha, Richard Halberg, Wei Xu, Paul Marker, Ting Fu
Xingchen Dong, Ming Qi, Chunmiao Cai, Yu Zhu, Yuwenbin Li, Sally Coulter, Fei Sun, Christopher Liddle, Nataliya V. Uboha, Richard Halberg, Wei Xu, Paul Marker, Ting Fu
View: Text | PDF
Research Article Endocrinology Gastroenterology

Farnesoid X receptor mediates macrophage-intrinsic responses to suppress colitis-induced colon cancer progression

  • Text
  • PDF
Abstract

Bile acids (BAs) affect the intestinal environment by ensuring barrier integrity, maintaining microbiota balance, regulating epithelium turnover, and modulating the immune system. As a master regulator of BA homeostasis, farnesoid X receptor (FXR) is severely compromised in patients with inflammatory bowel disease (IBD) and colitis-associated colorectal cancer (CAC). At the front line, gut macrophages react to the microbiota and metabolites that breach the epithelium. We aim to study the role of the BA/FXR axis in macrophages. This study demonstrates that inflammation-induced epithelial abnormalities compromised FXR signaling and altered BAs’ profile in a mouse CAC model. Further, gut macrophage–intrinsic FXR sensed aberrant BAs, leading to pro-inflammatory cytokines’ secretion, which promoted intestinal stem cell proliferation. Mechanistically, activation of FXR ameliorated intestinal inflammation and inhibited colitis-associated tumor growth, by regulating gut macrophages’ recruitment, polarization, and crosstalk with Th17 cells. However, deletion of FXR in bone marrow or gut macrophages escalated the intestinal inflammation. In summary, our study reveals a distinctive regulatory role of FXR in gut macrophages, suggesting its potential as a therapeutic target for addressing IBD and CAC.

Authors

Xingchen Dong, Ming Qi, Chunmiao Cai, Yu Zhu, Yuwenbin Li, Sally Coulter, Fei Sun, Christopher Liddle, Nataliya V. Uboha, Richard Halberg, Wei Xu, Paul Marker, Ting Fu

×

Figure 6

Gut macrophage–intrinsic FXR senses BA and regulates macrophage pro-inflammatory responses.

Options: View larger image (or click on image) Download as PowerPoint
Gut macrophage–intrinsic FXR senses BA and regulates macrophage pro-infl...
(A) Experimental scheme of gut macrophages enriched from small intestine of WT mice and subjected to various BAs for 6 hours. (B) Expression of pro-inflammatory cytokines and M1-like cell marker genes measured by qRT-PCR in gut macrophages treated with a gradient concentration of indicated BAs. (C) Experimental scheme of gut macrophages enriched from small intestine of WT and FXR-KO mice under 5 days of DSS administration and 2 days of recovery, then subjected to FXR agonist treatment for 18 hours. (D) Secreted (IL6, TNF-α) and intracellular (IL1β) cytokines were measured by ELISA in gut macrophages. (E and F) Expression of M1-like (E) and M2-like (F) marker genes by qRT-PCR in gut macrophages with above treatment. (G) Expression of M1-like marker genes by qRT-PCR in FXR-deficient (FXR-KO) gut macrophages. n = 3/group. Experiments were independently replicated 3 times, and representative data are shown as the mean ± SEM. P values are computed with 1-way ANOVA test followed by Tukey’s multiple comparisons; *M1/M2 versus M0 in WT or FXR-KO groups, *P < 0.05; **P < 0.01; ***P < 0.005.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts